Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.70 |
| ▸ | GSK3B | P49841 | 12/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.70 |
| ▸ | SRC | P12931 | 7/20 | 0.70 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.70 |
| ▸ | GSK3A | P49840 | 1/20 | 0.70 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.66 |
| ▸ | PLK4 | O00444 | 1/20 | 0.62 |
| ▸ | PAK4 | O96013 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147253 | 1.00 | AURKA (0.70) | AURKAGSK3BAURKBSRCEIF2AK2 | |
| SCHEMBL22054562 | 0.85 | AURKA (0.71) | AURKAGSK3BAURKBSRCEIF2AK2 | |
| SCHEMBL30147254 | 0.85 | AURKA (0.71) | AURKAGSK3BAURKBSRCEIF2AK2 | |
| SCHEMBL31471763 | 0.84 | AURKA (0.50) | AURKAGSK3BAURKBSRCEIF2AK2 | |
| SCHEMBL25819399 | 0.84 | AURKA (0.51) | AURKAGSK3BAURKBSRCEIF2AK2 | |
| SCHEMBL31471743 | 0.83 | AURKA (0.50) | AURKAGSK3BAURKBSRCEIF2AK2 | |
| SCHEMBL22054198 | 0.83 | PLK4 (0.62) | AURKAGSK3BAURKBSRCEIF2AK2 | |
| SCHEMBL22055218 | 0.83 | NTRK1 (0.59) | AURKAGSK3BAURKBSRCEIF2AK2 | |
| SCHEMBL30147250 | 0.83 | NTRK1 (0.59) | AURKAGSK3BAURKBSRCEIF2AK2 | |
| SCHEMBL4073913 | 0.83 | SPAST (0.58) | AURKAGSK3BAURKBSRCEIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025100889-A1 | QUINAZOLINE DERIVATIVE, SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2025-05-15 | — | — | WO | disclosed |
| CN-116354938-B | Preparation method and application of quinazoline derivatives and analogues thereof | 沈阳药科大学 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023123883-A1 | METHOD FOR PREPARING QUINAZOLINE DERIVATIVE AND ANALOG THEREOF AND USE THEREOF | 沈阳药科大学 | 2023-07-06 | — | — | WO | disclosed |
| CN-116354938-A | Preparation method and application of quinazoline derivatives and analogues thereof | 沈阳药科大学 | 2023-06-30 | — | — | CN | disclosed |
| CN-116003441-A | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115925705-A | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| CN-115667228-A | Salt and crystal form of heteroaromatic derivative and preparation method of salt and crystal form | 上海翰森生物医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-111511738-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-24 | — | — | US | disclosed |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
| WO-2002022604-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022607-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022605-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022603-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022601-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3A | AURKA 2/4885GSK3B 4/4885AURKB 7/4885 |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | MAP3K20, CDK2, MAP2K2 | AURKA 191/4885GSK3B 461/4885AURKB 291/4885 |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKA 2/4885GSK3B 3/4885AURKB 7/4885 |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | AURKA 1417/4885GSK3B 32/4885AURKB 584/4885 |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKA 2/4885GSK3B 3/4885AURKB 7/4885 |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, GSK3A, GSKIP | AURKA 255/4885GSK3B 1/4885AURKB 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.